Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene

Virology

Volumn 299, Issue 1, 2002, Pages 88-99

  Torresi, Joseph ^a,b,c   Earnest Silveira, Linda ^c   Civitico, Gilda ^d   Walters, Tomos E ^a,c   Lewin, Sharon R ^a,b   Fyfe, Janet ^c   Locarnini, Stephen A ^c   Manns, Michael ^e   Trautwein, Christian ^e   Bock, Thomas C ^e,f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^d Zenyth Therapeutics Limited Australia   (Australia)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS VACCINE; LAMIVUDINE; VIRUS DNA; VIRUS PROTEIN; VIRUS VECTOR;

ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DNA REPLICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOTOPE LABELING; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; VIRAL GENETICS; VIRUS INHIBITION; VIRUS MUTANT; WILD TYPE;

HEPATITIS B VIRUS; LETTUCE MOSAIC VIRUS;

EID: 0036038911     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1448     Document Type: Article

References (59)

1. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine
2. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase
3. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
4. The enhancer I core region contributes to the replication level of hepatitis B virus in vivo and in vitro
5. A PreS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly
6. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation
7. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase
8. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer
9. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
10. Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase
11. The clinical significance of surface antigen variants of hepatitis B virus
12. Vaccine-induced escape mutant of hepatitis B virus
13. Molecular modeling and biochemical characterisation reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)
14. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
15. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy
16. Lamivudine as initial treatment for chronic hepatitis B in the United States
17. Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase
18. Real-time quantitative RT-PCR after laser-assisted cell picking
19. A novel method for real time quantitative RT-PCR
20. Efficacy of long-term lamivudine mono-therapy in patients with hepatitis B e antigen-negative chronic hepatitis B
21. Real time quantitative PCR
22. The treatment of chronic viral hepatitis
23. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
24. A novel hepatitis B virus variant in the sera of immunized children
25. A one-year trial of lamivudine for chronic hepatitis B
26. Long-term therapy of chronic hepatitis B with lamivudine
27. Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed
28. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
29. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
30. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus
31. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
32. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy
33. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
34. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
35. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B
36. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy
37. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
38. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
39. Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase
40. Multicenter study of lamivudine therapy for hepatitis B virus after liver transplantation
41. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
42. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
43. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids
44. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
45. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
46. Inhibition of hepatitis B virus DNA polymerase by enantiomers of penciclovir triphosphate and metabolic basis for selective inhibition of HBV replication by penciclovir
47. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
48. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
49. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase: Implications for mechanisms of drug inhibition and resistance
50. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
51. Mutational analysis of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
52. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
53. Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy
54. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase
55. Surface variation of HBV: Scientific and medical relevance
56. Current status of HBV vaccine escape variants - A mathematical model of their epidemiology
57. Effect of alpha-interferon treatment in patients with hepatitis Be antigen-positive chronic hepatitis B: A meta-analysis
58. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
59. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy